111In and 131I labeled nimotuzumabs for targeted radiotherapy of a murine model of glioma

Watanabe N, Sawai H, Ogihara-Umeda I, Tanada S, Sasaki Y (2006) Molecular therapy of human neuroblastoma cells using Auger electrons of 111In-labeled N-myc antisense oligonucleotides. J Nucl Med 47:1670–1677

Aghevlian S, Lu YJ, Winnik MA, Hedley DW, Reilly RM (2018) Panitumumab modified with metal-chelating polymers (MCP) complexed to 111In and 177Lu-An EGFR-targeted theranostic for pancreatic cancer. Mol Pharm 15:1150–1159

Rosenkranz AA, Slastnikova TA, Karmakova TA, Vorontsova MS, Morozova NB, Petriev VM, Abrosimov AS, Khramtsov YV, Lupanova TN, Ulasov AV, Yakubovskaya RI, Georgiev GP, Sobolev AS (2018) Antitumor activity of auger electron emitter 111In delivered by modular nanotransporter for treatment of bladder cancer with EGFR overexpression. Front Pharmacol 9:1331

Liang RX, Liao ZH, Li FZ, Ma H, Liu WH, Chen XJ, Lan T, Yang YY, Liao JL, Yang JJ, Liu N (2022) In vitro anticancer ability of nano fluorescent 111In-MIL-68/PEG-FA on hela cells. Chem Eur J 28:e202104589

Hindie E, Zanotti-Fregonara P, Quinto MA, Morgat C, Champion C (2016) Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: implications for radiopharmaceutical therapy. J Nucl Med 57:759–764

Kassis AI (2011) Molecular and cellular radiobiological effects of Auger emitting radionuclides. Radiat Prot Dosim 143:241–247

Tang Y, Liu WH, Li FZ, Chen L, Wang MS, Hu YJ, Liao ZH, Chen Y, Li SF, Liao JL, Yang JJ, Yang YY, Liu N (2019) Indium-111 labeled bleomycin for targeting diagnosis and therapy of liver tumor: optimized preparation, biodistribution and SPECT imaging with xenograft models. J Radioanal Nucl Chem 322:545–551

Teunissen JM, Kwekkeboom DJ, de Jong M, Esser J-P, Valkema R, Krenning EP (2005) Peptide receptor radionuclide therapy. Best Pract Res Cl Ga 19:595–616

Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M (2005) 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 32:1288–1295

Banerjee SR, Kumar V, Lisok A, Plyku D, Novakova Z, Brummet M, Wharram B, Barinka C, Hobbs R, Pomper MG (2019) Evaluation of 111In-DOTA-5D3, a surrogate SPECT imaging agent for radioimmunotherapy of prostate-specific membrane antigen. J Nucl Med 60:400–406

Liao ZH, Li FZ, Tang Y, Liu WH, Gao J, Lan T, Yang JJ, Liao JL, Liu N, Yang YY (2021) Preliminary in vitro comparison of 111In and 131I labeled nimotuzumabs. J Radioanal Nucl Chem 328:527–537

Kayano D, Kinuya S, Kayano D (2018) Current consensus on I-131 MIBG therapy. Nucl Med Mol Imaging 52:254–265

Ma H, Li FZ, Shen GH, Cai HW, Liu WH, Lan T, Yang YY, Yang JJ, Liao JL, Liu N (2021) Synthesis and preliminary evaluation of 131I-labeled FAPI tracers for cancer theranostics. Mol Pharm 18:4179–4187

Kayano D, Kinuya S (2018) Current consensus on I-131 MIBG therapy. Nucl Med Mol Imaging 52:254–265

Gao J, Liao ZH, Liu WH, Hu YJ, Ma H, Xia LT, Li FZ, Lan T, Yang YY, Yang JJ, Liao JL, Liu N (2021) Simple and efficient method for producing high radionuclidic purity 111In using enriched 112Cd target. Appl Radiat Isot 176:109828

Li FZ, Yang YY, Liao JL, Liu N (2022) Recent progress of astatine-211 in endoradiotherapy: great advances from fundamental properties to targeted radiopharmaceuticals. Chin Chem Lett 33:3325–3338

Ma H, Li FZ, Shen GH, Pan LL, Liu WH, Liang RX, Lan T, Yang YY, Yang JJ, Liao JL, Liu N (2022) In vitro and in vivo evaluation of 211At-labeled fibroblast activation protein inhibitor for glioma treatment. Bioorg Med Chem 55:116600

Liu WH, Ma H, Liang RX, Chen XJ, Li HY, Lan T, Yang JJ, Liao JL, Qin Z, Yang YY, Liu N, Li FZ (2022) Targeted alpha therapy of glioma using 211At-labeled heterodimeric peptide targeting both VEGFR and integrins. Mol Pharm 19:3206–3216

Cai WB, Chen K, Mohamedali KA, Cao QZ, Gambhir SS, Rosenblum MG, Chen XY (2006) PET of vascular endothelial growth factor receptor expression. J Nucl Med 47:2048–2056

Lin JL, Bent BE (1992) Carbon-halogen bond dissociation on copper surfaces: effect of alkyl chain length. J Phys Chem 96:8529–8538

Glockler G (1959) Carbon-halogen bond energies and bond distances. J Phys Chem 63:828–832

Olafsen T, Bruland ØS, Zalutsky MR, Sandlie I (1996) Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: application to radiolabeling. Acta Oncol 35:297–301

Nikula TK, Bocchia M, Curcio MJ, Sgouros G, Ma Y, Finn RD (1995) Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity. Mol Immunol 32:865–872

Olafsen T, Bruland ØS, Zalutsky MR, Sandlie I (1995) Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Location of lysine residues and implications for radiolabeling. Nucl Med Biol 22:765–771

Shih YH, Peng CL, Lee SY, Chiang PF, Yao CJ, Lin WJ, Luo TY, Shieh MJ (2015) 111In-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma. Oncotarget 6:16601–16610

van Dijk LK, Boerman OC, Franssen GM, Kaanders JH, Bussink J (2015) 111In-cetuximab-F(ab’)2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model. J Nucl Med 56:287–292

van Dijk LK, Hoeben BA, Kaanders JH, Franssen GM, Boerman OC, Bussink J (2013) Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab’)2. J Nucl Med 54:2118–2124

Cornelissen B, Waller A, Target C, Kersemans V, Smart S, Vallis KA (2012) 111In-BnDTPA-F3 an Auger electron-emitting radiotherapeutic agent that targets nucleolin. EJNMMI Res 2:9